Thrive Health and Wellness, LLC dba Thrive Health Solutions
Has Thrive Health Solutions received an FDA warning letter? Yes. FDA issued a warning letter dated February 9, 2026 concerning products containing tirzepatide.
Letter facts
- Letter date
- February 9, 2026 (2026-02-09)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Compounding Pharmacy
- Products named
- NAD+ 50 mg/mLMEGALean (Tirzepatide/Cyanocobalamin) Injections 10mg/20mg/mLrepackaged sterile drug products
- Violation categories
- Unapproved new drugMisbrandingCGMP / insanitary conditions
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
CGMP / insanitary conditions
FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.
Factual Violation Summary
FDA says sterile drugs repackaged under insanitary conditions: aseptic filling outside ISO 5, no media fills, carpeted facility, non-sterile gloves/wipes, no sporicidal agent; products also unapproved and misbranded.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Adulterated drug products (insanitary conditions)
- Unapproved new drug products
- Misbranded drug products
More letters about Tirzepatide
Recent FDA warning letters concerning Tirzepatide:
- RonanRxOctober 30, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.